In order to provide you with a better browsing experience and to improve our site functionality, we use cookies and other tracking technologies. Detailed information on the use of cookies on our site and how to opt out is provided in our Cookie Policy. By clicking on "AGREE" button below or clicking into any content on this site, you consent that we can store and access cookies and other tracking technologies as described in our Cookie Policy.

Fujifilm Group Companies Perseus Proteomics and FUJIFILM RI Pharma Present the Development of a New Radiolabeled antibody*1 for Treating Lung Cancer to the SNM Annual Meeting in U.S.

มิถุนายน 08, 2553

Perseus Proteomics Inc. (President and CEO: Akiyuki Furuya; hereafter Perseus) and FUJIFILM RI Pharma Co., Ltd. (President and CEO: Misao Tsuda), which are the subsidiaries of FUJIFILM Corporation (President and CEO: Shigetaka Komori), presented their development of a new radiolabeled antibody*1 for treating lung caner to the meeting of the Society of Nuclear Medicine (SNM)*2, convened in Salt Lake City, United States on June 7 (June 8, Japan time).

Perseus found the protein which specifically expressed in cancer tissue by analyzing human gene expression profiling*3, collaborating with the Research Center for Advanced Science and Technology, University of Tokyo. They successfully identified a protein that characteristically appear in cancerous cells, and found that it is expressed in lung cancer, pancreatic cancer, colon cancer and a wide range of cancers at a high rate. Perseus then produced antibodies against the protein, and succeeded, in a joint research with FUJIFILM RI Pharma, in radiolabeling the antibodies that demonstrate a high level of accumulation in cancer cells while having a minimal effect on normal tissues, with Yttrium (Y-90*4). The company decided to present this research outcome this time after confirming that these "armed antibodies*5" can significantly inhibit tumor growth in mouse lung cancer models*6

In recent years, the pharmaceutical market for antibody drugs is expanding significantly as their characteristic of targeting specific cells or tissues offers advanced safety and treatment efficacy. Cancer has few drugs that produce satisfactory results because of its sophisticated multiplication mechanism. Expectations are running high for armed antibodies, which combines antibodies that accumulate in cancerous cells with radioisotope or anti-cancer agent.

The Fujifilm Group is amassing its resources to the Armed antibody developed further as a promising candidate for antibody contributing to the therapy of lung cancer. The Group will continue to tap into its advanced technologies and rich experiences to deliver optimum solutions featuring proprietary technologies, and to further improve people's quality of life.

  • *1 Radiolabeled antibody : Antibody coupled with radioisotope (RI) to enhance pharmaceutical efficacy
  • *2 Society of Nuclear Medicine : The world's largest academic society on the diagnostic or therapeutic use of nuclear medicine
  • *3 Human gene expression profiling: A method that compares cancer cells with normal protein cells based on genetic information to analyze the difference in the amount of proteins
  • *4 Radioisotope (RI) for medical treatment
  • *5 Next-generation antibody drugs that combine antibodies that accumulate in pathogen-affected tissues at high concentration with RI, toxin, anti-cancer agent, etc. to deliver high pharmaceutical efficacy than the antibodies themselves
  • *6 Mouse models of lung cancer : A model for evaluating cancer cells in which human lung cancer cells are transplanted to mice under the skin

For enquiries on information in this media release, contact:

Media Contact:
FUJIFILM Corporation
Corporate Public Relations Group
TEL: +81-3-6271-2000
Other Enquiries:
Life Science Business Division
TEL: +81-3-6271-2158